Do We Already Have A Drug That Could Epigenetically Erase Traumatic Memories?

Same Drug Used to Treat Multiple Sclerosis May Delete Adverse Memories

HDAC histone acetylation epigenetic drug

Scientists at the Virginia Commonwealth University School of Medicine discovered that the drug fingolimod, which is used to treat multiple sclerosis (MS), could potentially benefit individuals who wish to get rid of painful and traumatic memories. While MS is still not entirely understood, the disease involves a process that is immune-mediated in which the immune system attacks healthy parts of the body, namely the central nervous system – the spinal cord, brain, and optic nerves. Fingolimod, or FTY720, is a drug that acts to suppress the immune system, thereby potentially treating MS.

In a study published in Nature Neuroscience, researchers found that this drug could have an additional molecular function, aside from its involvement in the immune system. Using a mouse model, the team demonstrated that fingolimod can accumulate in the brain and lead to the inhibition of class 1 histone deactylases (HDACs), enhancing specific histone acetylations. They also found an increase in the expression of a number of genes relevant to memory processes.

Corresponding author and renowned researcher, Sarah Spiegel, Ph.D., notes that the positive effects of fingolimod are not fully understood and this newly discovered activity may mediate the drug’s beneficial effects.

“It will be important in the future to determine whether this prodrug can reduce loss of cognitive functions and can erase adverse memories,” she said.

Although they have been used to treat neurological and psychiatric disorders, histone deactylase inhibitors’ mechanisms of effectiveness are not entirely understood.

“FTY720/fingolimod may be a useful adjuvant therapy to help stop aversive memories such as in post-traumatic stress disorder and other anxiety disorders,” Spiegel indicates. She also cautions that “the work has not been extended to show effectiveness in humans at this time.”

Researchers are still working on unraveling the mystery of the exact molecular underpinnings linked to fingolimod’s effect on memory.
Source: Learn all about it and read more about their findings here: Active, phosphorylated fingolimod inhibits histone deacetylases and facilitates fear extinction memory. Hait, N. C., et al. 2014.

References: Virginia Commonwealth University News. Basic research shows that drug used to treat multiple sclerosis may have beneficial effects on memory. 2014. National Multiple Sclerosis Society. What is MS?.

Related Articles

Bailey Kirkpatrick
About Bailey Kirkpatrick 164 Articles
Bailey Kirkpatrick is the Senior Editor at What Is Epigenetics and a science writer with a background in epigenetics and psychology with a passion for conveying scientific concepts to the wider community. She enjoys speculating about the implications of epigenetics and how it might impact our perception of wellbeing and the development of novel preventative strategies. When she’s not combing through research articles, she also enjoys discovering new foods, taking nighttime strolls, and discussing current events over a barrel-aged sour beer or cold-brewed coffee.

WIE-logo-icon

If you like reading our articles…

Join our e-newsletter! Stay up-to-date with our weekly posts on epigenetics and health, nutrition, exercise, and more.

More in Diseases & Disorders, Drugs & Addiction, News & Reviews
dna methylation breast cancer epigenetic research solved puzzle
Scientists Solve 30 Year Old Breast Cancer Riddle

Scientists at the Fred Hutchinson Cancer Research Center found that mice lacking one copy of a gene called CTCF have...

Close